New England Capital Financial Advisors’s Verrica Pharmaceuticals VRCA Stock Holding History

New England Capital Financial Advisors’s Portfolio VRCA Stock Details VRCA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.22K	Hold	200	–	–	﹤0.01%	378
2026 Q1	$1.06K	Hold	200	–	–	﹤0.01%	375
2025 Q4	$1.66K	Hold	200	–	–	﹤0.01%	360
2025 Q3	$862	Buy	+200	New	+$1.21K	﹤0.01%	371
2025 Q2	–	Sell	-200	Closed	-$885	–	428
2025 Q1	$885	Hold	200	–	–	﹤0.01%	339
2024 Q4	$1.4K	Buy	+200	New	+$2.2K	﹤0.01%	340

Other funds holding VRCA

APW

Allied Private Wealth Boca Raton, Florida $156M AUM

IAIM

International Assets Investment Management Orlando, Florida $1.67B AUM 28.26% 1-Year Est. Return

FFO

Fortitude Family Office Scottsdale, Arizona $516M AUM 28.38% 1-Year Est. Return

VNA

Valley National Advisers Bethlehem, Pennsylvania $900M AUM 31.19% 1-Year Est. Return

New England Capital Financial Advisors's VRCA Position: Q2 2026 in Review

New England Capital Financial Advisors held its Verrica Pharmaceuticals (VRCA) position steady in Q2 2026 at 200 shares worth $1.22K. The position accounts for ﹤0.01% of the portfolio, ranked #378.

New England Capital Financial Advisors first reported a position in VRCA in Q4 2024 and has held it in 6 quarters since. The position peaked at $1.66K in Q4 2025. 5 funds tracked by Wall St. Rank hold VRCA as of Q2 2026.

New England Capital Financial Advisors held 200 shares of Verrica Pharmaceuticals worth $1.22K as of Q2 2026.
New England Capital Financial Advisors left its Verrica Pharmaceuticals share count unchanged in Q2 2026.
Verrica Pharmaceuticals made up ﹤0.01% of New England Capital Financial Advisors's portfolio in Q2 2026, its #378 holding.
New England Capital Financial Advisors first reported a position in Verrica Pharmaceuticals in Q4 2024 and has held it in 6 quarters since.
New England Capital Financial Advisors's Verrica Pharmaceuticals position peaked at $1.66K in Q4 2025.
5 funds tracked by Wall St. Rank held Verrica Pharmaceuticals as of Q2 2026.

Based on New England Capital Financial Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.